VERTEX PHARMACEUTICALS INC / MA

VRTX · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $110.5B · 6,400 employees
81
SEC Filings
$436.27
Close 2026-04-10
6,400
Employees

Business Summary

Vertex Pharmaceuticals is a global biotechnology company focused on transformative medicines for serious diseases. It markets TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO for cystic fibrosis; CASGEVY (gene-editing therapy) for sickle cell disease and transfusion-dependent beta thalassemia; and JOURNAVX (suzetrigine) for acute pain. The company also has a mid- and late-stage pipeline targeting IgA nephropathy, APOL1-mediated kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, and other serious diseases.

Latest Stock Quote

VRTX 2026-04-10 $436.27 O:$446.08 H:$446.75 L:$434.25 Vol:1.0M VWAP:$438.1666
origin leaf: 39c8bc04c90fc615307a4612717ad3b9b03d80016544640bb76d8edfe89f6ed8

Next Earnings

expected 2026-08-07

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionVRTXdiscussed_in_filing Cybersecurity
topic_mentionVRTXdiscussed_in_filing Trusted Computing
topic_mentionVRTXdiscussed_in_filing Blockchain & Crypto
topic_mentionVRTXdiscussed_in_filing Regulation
topic_mentionVRTXdiscussed_in_filing Healthcare & Bio
topic_mentionVRTXdiscussed_in_filing Cybersecurity
topic_mentionVRTXdiscussed_in_filing Trusted Computing
topic_mentionVRTXdiscussed_in_filing Blockchain & Crypto
topic_mentionVRTXdiscussed_in_filing Regulation
topic_mentionVRTXdiscussed_in_filing Healthcare & Bio
topic_mentionVRTXdiscussed_in_filing Cybersecurity
topic_mentionVRTXdiscussed_in_filing Trusted Computing
topic_mentionVRTXdiscussed_in_filing Blockchain & Crypto
topic_mentionVRTXdiscussed_in_filing Regulation
topic_mentionVRTXdiscussed_in_filing Healthcare & Bio
topic_mentionVRTXdiscussed_in_filing Cybersecurity
topic_mentionVRTXdiscussed_in_filing Trusted Computing
topic_mentionVRTXdiscussed_in_filing Blockchain & Crypto
topic_mentionVRTXdiscussed_in_filing Regulation
topic_mentionVRTXdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-132025-12-310000875320-26-000056EDGAR68K words
2025-02-132024-12-310000875320-25-000053EDGAR—
2024-02-152023-12-310000875320-24-000062EDGAR—
2023-02-102022-12-310000875320-23-000007EDGAR—
2022-02-092021-12-310000875320-22-000007EDGAR—
2021-02-112020-12-310000875320-21-000006EDGAR—
2020-02-132019-12-310000875320-20-000007EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300000875320-25-000232EDGAR23K words
2025-08-052025-06-300000875320-25-000216EDGAR—
2025-05-062025-03-310000875320-25-000192EDGAR—
2024-11-052024-09-300000875320-24-000223EDGAR—
2024-08-022024-06-300000875320-24-000198EDGAR—
2024-05-072024-03-310000875320-24-000139EDGAR—
2023-11-072023-09-300000875320-23-000031EDGAR—
2023-08-022023-06-300000875320-23-000021EDGAR—
2023-05-022023-03-310000875320-23-000012EDGAR—
2022-10-282022-09-300000875320-22-000038EDGAR—
2022-08-052022-06-300000875320-22-000030EDGAR—
2022-05-062022-03-310000875320-22-000014EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310000875320-26-000147EDGAR1K words
2026-02-120000875320-26-000034EDGAR—
2025-11-030000875320-25-000230EDGAR—
2025-08-040000875320-25-000213EDGAR—
2025-05-190000875320-25-000199EDGAR—
2025-05-140000875320-25-000194EDGAR—
2025-05-050000875320-25-000171EDGAR—
2025-03-280000875320-25-000156EDGAR—
2025-02-100000875320-25-000029EDGAR—
2024-12-200000875320-24-000231EDGAR—

81 total filings indexed. 52 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

cystic-fibrosis sickle-cell-disease transfusion-dependent-beta-thalassemia acute-pain iga-nephropathy apol1-mediated-kidney-disease peripheral-neuropathic-pain type-1-diabetes primary-membranous-nephropathy autosomal-dominant-polycystic-kidney-disease myotonic-dystrophy-type-1 crispr/cas9-gene-editing cftr-modulation nav1.8-selective-inhibition allogeneic-stem-cell-derived-islet-cell-therapy

Company Identity

CIK0000875320
TickerVRTX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedMA
Websitehttps://www.vrtx.com
Listed1991-07-31

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 02c7d873041816cd867530de45e89262f947784f87d98139384e1d90f784418e
parent: 67773103235fc697f49785f58a38ae9ceda0e78d02df4d9770ac5dc00da68f78
content hash: c8caea75643184ee90b53fe1a538191d6b8ca73e4540867d35b012d4f8eea5d8
signed: 2026-04-13T04:48:08.535Z
sources: 20 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf